Global X HealthTech ETF (HEAL)

What companies does HEAL actually hold?

HEAL follows the Global X HealthTech Index, which holds approximately 43 exchange-listed companies in the healthcare technology space. The top holdings provide a window into the strategy: DexCom (continuous glucose monitors), GE HealthCare Technologies (medical imaging and diagnostics), IQVIA Holdings (contract research and data analytics for drug development), TransMedics Group (organ transplant preservation systems), and iRhythm Technologies (cardiac monitoring devices). These five holdings represent roughly 22 percent of the fund. The fund is diversified across multiple companies, avoiding concentration in any single stock, though the largest holdings carry material weight.

What does “HealthTech” actually mean here?

HealthTech is broader than medical devices or pharmaceutical software. The Global X HealthTech Index defines it as companies positioned to benefit from advances in healthcare technology and their applications. This encompasses four sub-themes: artificial intelligence and machine learning applied to drug discovery and clinical research; smart medical devices such as remote monitors and diagnostic instruments; technology-enabled consumer healthcare platforms and telemedicine; and healthcare analytics and software solutions that help hospitals, insurers, and pharmaceutical firms operate more efficiently. A company might fit multiple sub-themes. IQVIA, for example, blends AI-powered drug development, analytics, and data management.

How does HEAL’s index construction work?

HEAL is a passively managed, index-tracking fund. It invests at least eighty percent of its total assets in the securities of the underlying Global X HealthTech Index, which is maintained by the Index Administrator. The index uses a rules-based methodology to select and weight holdings, meaning the fund does not rely on human judgment about which healthcare technology companies will outperform. Decisions about which companies enter the index and how much weight each receives follow a predetermined set of criteria rather than active management calls. This keeps the fund’s expense ratio low and ensures transparency — investors can examine the index methodology and know exactly which companies are eligible.

What makes healthcare tech different from general healthcare investing?

A traditional healthcare equity fund might hold large pharmaceutical companies, hospital systems, and medical device makers — the incumbent institutions of the healthcare economy. HEAL is narrower: it holds companies specifically positioned around technological change and innovation within healthcare. This could mean a software company selling diagnostic algorithms to radiology departments, a device manufacturer using machine learning to improve accuracy, or a contract research firm specializing in AI-accelerated drug development. The lens is technology’s impact on healthcare delivery and discovery, not healthcare’s impact on investors. A company like Merck or Johnson & Johnson, which are pharmaceutical and device incumbents but not primarily technology innovators, would not be in HEAL. A biotech startup with novel AI discovery tools would be.

What are the real risks in this fund?

HEAL concentrates in a subset of healthcare — the technology-forward companies — which means it likely underweights traditional medical device makers and hospital operators. If cutting-edge technology adoption in healthcare stalls, or if capital dries up for high-growth healthcare tech startups, the fund could underperform a broader healthcare fund. Many of HEAL’s holdings are smaller or mid-cap companies with higher volatility and less stable earnings than defensive healthcare giants. Individual holding risk is higher. Additionally, healthcare technology is heavily regulated: FDA clearances, insurance reimbursement decisions, and privacy regulations can help or hinder any single holding. Regulatory setbacks at a concentrated holding can ripple through the fund. The fund also lacks the dividend yield often found in traditional healthcare, so returns depend more on capital appreciation.

How should a reader research HEAL?

Start with the prospectus and fact sheet from Global X, which detail the index methodology, the current holdings, and the expense ratio. Review the latest holdings report to see which companies have the largest positions and research those individually — understanding DexCom’s revenue drivers and GE HealthCare’s competitive position is foundational to understanding HEAL’s exposure. Next, read the Global X website’s educational materials on why healthcare technology matters: the company has published articles on artificial intelligence in drug discovery, remote patient monitoring, and digital health adoption that spell out the investment thesis. For deeper dives, look at individual company earnings calls and investor presentations — these reveal how much of a company’s growth story is actually driven by healthcare technology adoption versus other factors. Finally, watch healthcare regulatory news — FDA rulings, Medicare reimbursement changes, and privacy regulations often move healthcare tech stocks, and understanding what to expect is essential context.